Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Authors' reply

BMJ

Volumn 328, Issue 7450, 2004, Pages 1260-

  Plowe, Christopher V ^a   Kublin, James G ^a   Dzinjalamala, Fraction K ^b   Kamwendo, Deborah S ^b   Mukadam, Rabia A G ^b   Chimpeni, Phillips ^b   Molyneux, Malcolm E ^c   Taylor, Terrie E ^d  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

^c MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007683045     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.328.7450.1260     Document Type: Letter

References (3)

1. World Health Organization Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Geneva, World Health Organization, Division of Control of Tropical Diseases, 1996.
2. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, et al Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 2002; 360: 1136-43.
3. Statistics Division, World Health Organization. Millennium indicators database. http://unstats.un.org/unsd/mi/mi_goals.asp (accessed 6 May 2004).